INSYS Therapeutics
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, INSYS Therapeutics sits in the top decile of US sponsors by registered trial count (#473 of 15,742 sponsors by registered trial count).
INSYS Therapeutics: 35 sponsored US clinical trials, none currently recruiting.
INSYS Therapeutics sponsors 35 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 32 completed. 7 of these trials are in Phase 3-4 (later-stage) and 26 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Neoplasms, with 2 trials.
Top-decile sponsor footprint
INSYS Therapeutics ranks in the top decile of sponsors by registered trial count (#473 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
32 of 35 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
35 total, page 1 of 1
A Study to Compare Bioavailability of Naloxone Nasal Spray, Naloxone Hydrochloride (HCl) Intravenous (IV) and Intramuscular Injection (IM) in Healthy Volunteers
NCT03827642
Study of Buprenorphine Sublingual Spray Versus Standard of Care Narcotic Therapy for the Treatment of Post-Operative Pain
NCT03254459
A Study to Compare Bioavailability of Naloxone Nasal Spray and Naloxone Hydrochloride (HCl) Intramuscular Injection (IM) in Healthy Volunteers
NCT03827629
Fentanyl Sublingual Spray for the Treatment of Moderate to Severe Post-Operative Pain
NCT02915978
Study of Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain
NCT02634788
Cannabidiol Oral Solution for Treatment of Refractory Infantile Spasms
NCT02551731
Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder
NCT02318602
Fentanyl Sublingual Spray in Opioid Naive Participants
NCT02641340
Comparative Bioavailability of Dronabinol Oral Solution in Healthy Volunteers
NCT02604992
Fentanyl Sublingual Spray and Fentanyl Citrate Intravenous (IV) in Opioid Naive Subjects
NCT02576353
Study of Buprenorphine-Naloxone Sublingual Spray and Suboxone® Sublingual Film in Healthy Volunteers
NCT02477267
Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders
NCT02324673
Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain
NCT02310581
Exploratory Bioavailability of Fentanyl Sublingual Spray Under Fasting Conditions
NCT02138396
Possible New Therapy for Advanced Cancer
NCT01832974
Comparative Bioavailability of Dronabinol Oral Solution Versus Branded Capsule 5 mg Under Fasting Conditions
NCT01448772
Efficacy and Safety Study of LE-DT to Treat Locally Advanced or Metastatic Pancreatic Cancer
NCT01186731
Fentanyl Sublingual Spray in Treating Opioid-tolerant Cancer Patients With or Without Oral Mucositis
NCT00956254
Liposome Encapsulated Docetaxel (LE-DT) in Patients With Solid Tumors
NCT01151384
Long-term Safety and Efficacy Study of Fentanyl Sublingual Spray for the Treatment of Breakthrough Cancer Pain
NCT00538863
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
NCT00538850
Pharmacokinetic Study of Fentanyl 400 µg Sublingual Spray, Actiq® 400 µg Transmucosally, and Fentanyl Citrate Injection 100 µg Intravenously (iv)
NCT01780233
Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Cancer
NCT00100672
Comparison of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) and Taxol® Pharmacokinetics in Patients With Advanced Cancer
NCT00100139
IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma
NCT00089427
The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme
NCT00076986
Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) in Patients With Advanced Cancer
NCT00080418
Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma
NCT00064779
Liposome Encapsulated SN38 (LE-SN38) in Patients With Advanced Cancer
NCT00046540
Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma
NCT00041587
Study of Liposome Encapsulated Mitoxantrone (LEM) in Patients With Advanced Cancer
NCT00024492
Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients
NCT00024557
Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Solid Tumors
NCT00024661
Study to Determine Maximum Tolerated Dose of LErafAON Combined With Radiotherapy in Patients With Advanced Malignancies
NCT00024648
Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma
NCT00024570
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 22 |
| Phase 2 | 4 |
| Phase 3 | 7 |
Therapeutic Areas
How the INSYS Therapeutics early-phase archive is shaped
35 indexed studies, none listed as recruiting (0% open); 32 completed (91%).
Phase mix: 7 late (III/IV) vs 26 early (I/II) (early-phase heavy).
Top condition: Neoplasms (2 trials), 6 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
INSYS Therapeutics: archived-pipeline peers nationwide
Peers matched on 35 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
INSYS Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 35 archived trials
- ACADIA Pharmaceuticals · 35 trials · 9% recruiting
- Merz North America · 35 trials · 3% recruiting
- Palo Alto Veterans Institute for Research · 35 trials · 20% recruiting
- Philips Respironics · 35 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this INSYS Therapeutics page
35 registered trials is a research-attention snapshot, not an endorsement of INSYS Therapeutics or any single study.
- None of INSYS Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Neoplasms is the condition INSYS Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Neoplasms trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. INSYS Therapeutics pipeline card: 35 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.